1Bellamy W,List A,Grogan T.Expression of VEGF and its receptors in myeloma.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
2Tosi P,Ronconi S,Zamagni E,et al.Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation[].Haematologica.2001
3Rajkumar S V,Leong T,Roche P C,et al.Prognostic value of bone marrow angiogensis in multiple myeloma[].Clinical Cancer Research.2000
4Schreiber S,Ackermann J,Obermair A,et al.Multiple myeloma with eletion of chromosome 13q is characterized by ineased bone marrow neovascularization[].British Journal of Haematology.2000
5Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide: focus on palliative care[].Drugs.2000
6Celgene.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
7Faith E D,Noopur R,Teru H,et al.Thalidomide and immunmodulatory derivatives augment natral killer cell cytotoxicity in multiple myeloma[].Blood.2001
8Rajkumar S V,Witzig T E.A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma[].Cancer Treatment Reviews.2000
9Tosi P, Zamagni E, Cellini C. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure [ J ]. Eur J Hacmatol, 2004, 73(2) :98.
10The International Myeloma Working Group. Criteria for the classification of monoelonal gammopathies, multiple myeloma and related disorders:a report of the Intemfional Myeloma Working Group [ J ]. Br Haematol,2003 ,121:749 - 757,
